Vascular malformation

Lecanemab named one of the world's best inventions in 2023 by TIME

Retrieved on: 
Tuesday, October 24, 2023
Risk, Aneurysm, Vomiting, Cerebral edema, Focal neurologic signs, Incidence, Dementia, Nausea, Disease, Intraparenchymal hemorrhage, Intracerebral hemorrhage, CET, Chills, AI, Paracetamol, Hypersensitivity, Memory, Lecanemab, Vascular malformation, MRI, Excipient, Neuroimaging, Fatal, Thought, Dizziness, Aspirin, Edema, Anticoagulant, Cerebral amyloid angiopathy, Magnetic resonance imaging, Patient, Bronchospasm, Alzheimer's disease, Anaphylaxis, Genetic testing, TIME, ARIA, Arthralgia, Research, Eisai, Fever, Hypotension, Amyloid, Headache, Siderosis, Behavior, Invention, Observation, Hypertension, Confusion, Seizure, Angioedema, Status epilepticus, Tissue plasminogen activator, Pharmaceutical industry, Lace, Medical imaging, Copper

"It is a great honor and tremendous recognition that lecanemab is included in TIME's list of the world's best inventions this year.

Key Points: 
  • "It is a great honor and tremendous recognition that lecanemab is included in TIME's list of the world's best inventions this year.
  • TIME's annual list of the best inventions includes "200 extraordinary innovations changing lives."
  • The information was released for public disclosure, through the agency of the contact persons below, on October 24, 2023, at 4.50 p.m. CET.
  • ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur.

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

Retrieved on: 
Monday, September 25, 2023
Hypersensitivity, Status epilepticus, Intracerebral hemorrhage, Cerebral amyloid angiopathy, Arthralgia, Cerebral edema, Hypotension, Aneurysm, Risk, Focal neurologic signs, Chills, Fatal, Fever, Edema, Neuroimaging, AND, Angioedema, Siderosis, Tissue plasminogen activator, Aspirin, Hypertension, Vomiting, Incidence, Excipient, ARIA, Anticoagulant, MRI, Magnetic resonance imaging, Dizziness, Amyloid, Patient, Intraparenchymal hemorrhage, Anaphylaxis, Paracetamol, Seizure, Genetic testing, Confusion, Nausea, Observation, Lecanemab, Headache, Bronchospasm, Vascular malformation, Medical device, Pharmaceutical industry, Lace, Medical imaging, Copper

INDICATION, DOSAGE AND ADMINISTRATION, AND IMPORTANT SAFETY INFORMATION IN THE U.S.

Key Points: 
  • INDICATION, DOSAGE AND ADMINISTRATION, AND IMPORTANT SAFETY INFORMATION IN THE U.S.
    LEQEMBI is indicated for the treatment of Alzheimer’s disease.
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
  • ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur.
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE

Retrieved on: 
Tuesday, January 10, 2023
Cerebral edema, Intracerebral hemorrhage, Anticoagulant, Arthralgia, Aspirin, Stroke, MRI, Dizziness, Cerebral contusion, Seizure, Hypotension, Effectiveness, Status epilepticus, Diarrhea, Clopidogrel, Alzheimer's disease, Aneurysm, Risk, Vomiting, ARIA, Chills, AND, Disease, Nausea, Patient, Intracranial hemorrhage, Vascular malformation, Cough, Paracetamol, Hypertension, Focal neurologic signs, Headache, Observation, Incidence, Tissue plasminogen activator, Confusion, Siderosis, Fever, Medical device, Pharmaceutical industry, Medical imaging, Clothing

Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Key Points: 
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • In Study 1, 15% of LEQEMBI-treated patients, compared to 6% of placebo-treated patients, stopped study treatment because of an adverse reaction.

Doctors at Manipal Hospitals, Delhi successfully treats 6-year-old Iraqi girl for rare brain disease

Retrieved on: 
Wednesday, November 30, 2022
Hospital, Incidence, Skin, Scalp, Weakness, Ministry, Brain, Bed, Patient, NABL, Disease, Manipal Hospitals, Private company limited by shares, NABH, City, Bangalore, Vascular malformation, Family, Moyamoya disease, Stroke, Artery, ER, Acquisition, Blood bank, Health insurance, Health

NEW DELHI, Nov. 30, 2022 /PRNewswire/ --In a rare incidence, doctors at Manipal Hospitals, Delhi, successfully performed a special cerebral revascularization surgery on a 6-year-old girl from Iraq.

Key Points: 
  • NEW DELHI, Nov. 30, 2022 /PRNewswire/ --In a rare incidence, doctors at Manipal Hospitals, Delhi, successfully performed a special cerebral revascularization surgery on a 6-year-old girl from Iraq.
  • But, with the support from the Iraqi Ministry of Health, the family brought the little girl to India.
  • She was initially referred because of suspicion of a vascular malformation in her brain, but on further investigation, it was revealed that she was suffering from a rare condition called MoyaMoya Disease.
  • MoyaMoya Disease is a rare disease where the arteries supplying blood to the brain start to shrink.

Doctors at Manipal Hospitals, Delhi successfully treats 6-year-old Iraqi girl for rare brain disease

Retrieved on: 
Wednesday, November 30, 2022
Hospital, Incidence, Skin, Scalp, Weakness, Ministry, Brain, Bed, Patient, NABL, Disease, Manipal Hospitals, Private company limited by shares, NABH, City, Bangalore, Vascular malformation, Family, Moyamoya disease, Stroke, Artery, ER, Acquisition, Blood bank, Health insurance, Health

NEW DELHI, Nov. 30, 2022 /PRNewswire/ --In a rare incidence, doctors at Manipal Hospitals, Delhi, successfully performed a special cerebral revascularization surgery on a 6-year-old girl from Iraq.

Key Points: 
  • NEW DELHI, Nov. 30, 2022 /PRNewswire/ --In a rare incidence, doctors at Manipal Hospitals, Delhi, successfully performed a special cerebral revascularization surgery on a 6-year-old girl from Iraq.
  • But, with the support from the Iraqi Ministry of Health, the family brought the little girl to India.
  • She was initially referred because of suspicion of a vascular malformation in her brain, but on further investigation, it was revealed that she was suffering from a rare condition called MoyaMoya Disease.
  • MoyaMoya Disease is a rare disease where the arteries supplying blood to the brain start to shrink.